[R01] Immunotherapy for Glioblastoma by Targeting an Immunoregulatory Neuropeptide
Ente: National Cancer Institute
Scadenza: 2031-05-31
Importo max: $567,754
Paese: US
Descrizione
lioblastoma (GBM) is the most lethal primary brain tumor, marked by limited treatment options and poor
survival. GBM is also remarkably resistant to immunotherapy due to CD8⁺ T cell exclusion and dysfunction,
largely driven by immunosuppressive myeloid cells—particularly tumor-associated macrophages
Settori: National Cancer Institute
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.